Xoma | XOMA - Sales Revenues


Xoma reported $25K in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Agenus USD 34.2M 3.97M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Ardelyx USD 125.21M 14.89M Dec/2025
aTyr Pharma USD 110.08M 109.89M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Celldex Therapeutics USD 121K 769K Dec/2025
Curis USD 1.14M 1.41M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Incyte USD 1.51B 140M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Novartis USD 13.86B 498M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Prothena USD 21K 2.4M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Xoma USD 25K 5M Sep/2024